Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia

Psychopharmacology

Volumn 224, Issue 3, 2012, Pages 441-449

  Rajkumar, A P ^a,b,c   Poonkuzhali, B ^a   Kuruvilla, A ^a   Srivastava, A ^a   Jacob, M ^a   Jacob, K S ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Clozapine; HTR3A gene; Pharmacogenetics; Schizophrenia; Single nucleotide polymorphism

Indexed keywords

CLOZAPINE; SEROTONIN 3A RECEPTOR;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; DYSLIPIDEMIA; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; NAUSEA; NOCTURNAL ENURESIS; OBESITY; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; SEROTONIN 3A RECEPTOR GENE; SEXUAL DYSFUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; VOMITING;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CLOZAPINE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 84871647741     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2773-2     Document Type: Article

References (53)

1. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162:441-449
2. APA (2000) Diagnostic and statistical manual of mental disorders - fourth edition text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC
3. Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130-1144
4. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615-1616
5. Basile VS, Masellis M, Potkin SG, Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530
6. Briskin JK, Curtis JL (1997) Augmentation of clozapine therapy with ondansetron. Am J Psychiatry 154:1171
7. Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J (2001) When symptoms persist: clozapine augmentation strategies. Schizophr Bull 27:615-628
8. Burns T (2007) Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl 50:s1-s6
9. Conley RR, Carpenter WT Jr, Tamminga CA (1997) Time to clozapine response in a standardized trial. Am J Psychiatry 154:1243-1247
10. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397:359-363
11. de Leon J, Arranz MJ, Ruano G (2008) Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 28:599-617
12. Dratcu L, Grandison A, McKay G, Bamidele A, Vasudevan V (2007) Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 14:314-318
13. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33:766-771
14. Estellat C, Torgerson DJ, Ravaud P (2009) How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol 23:291-303
15. Feise RJ (2002) Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2:8
16. Foster A, Miller DD, Buckley PF (2007) Pharmacogenetics and schizophrenia. Psychiatr Clin North Am 30:417-435
17. Gauderman WJ (2002) Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 155:478-484
18. Gutierrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthiasson P, Travis M, Munro J, Osborne S, Kerwin RW (2002) Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 58:93-97
19. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975-981
20. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Hoschl C (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20:389-409
21. Hwang R, Shinkai T, De Luca V, Muller DJ, Ni X, Macciardi F, Potkin S, Lieberman JA, Meltzer HY, Kennedy JL (2005) Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 181:179-187
22. Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, Iwata N, Yamamoto Y, Okada T, Sadato N (2005) A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 25:6460-6466
23. Ioannidis JP, Trikalinos TA, Khoury MJ (2006) Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 164:609-614
24. Jacob KS (1994) The quest for the etiology of mental disorders. J Clin Epidemiol 47:97-99
25. Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, Inada T, Ozaki N (2008) Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 435:95-98
26. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
27. Kendler KS (2005) Toward a philosophical structure for psychiatry. Am J Psychiatry 162:433-440
28. Kilpatrick LA, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K, Bueller JA, Suyenobu B, Jarcho JM, McRoberts JA, Niesler B, Mayer EA (2011) The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome. Gastroenterology 140:1943-1951
29. Leucht S, Davis JM, Engel RR, Kane JM,Wagenpfeil S (2007) Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 32:1903-1910
30. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744-1752
31. Mancama D, Arranz MJ, Kerwin RW (2002) Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 16:317-324
32. Melke J, Westberg L, Nilsson S, Landen M, Soderstrom H, Baghaei F, Rosmond R, Holm G, Bjorntorp P, Nilsson LG, Adolfsson R, Eriksson E (2003) A polymorphism in the serotonin receptor 3A (HTR3A) gene and its association with harm avoidance in women. Arch Gen Psychiatry 60:1017-1023
33. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S (2003) Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82-91
34. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR (2006) The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21:1078-1085
35. NCBI-SNP (2011) Reference SNP cluster report: rs1062613 [Online]. National Library of Medicine (US). Available: http://www.ncbi.nlm.nih.gov/ projects/SNP/snp-ref.cgi?rs01062613. Accessed 28 Nov 2011
36. Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E, Albus M, Propping P, Rappold GA (2001) Association between the 5′ UTR variant C178T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 11:471-475
37. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812
38. Pennebaker JW, Susman JR (1988) Disclosure of traumas and psychosomatic processes. Soc Sci Med 26:327-332
39. Prasad S, Semwal P, Deshpande S, Bhatia T, Nimgaonkar VL, Thelma BK (2002) Molecular genetics of schizophrenia: past, present and future. J Biosci 27:35-52
40. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and populationbased linkage analyses. Am J Hum Genet 81:559-575
41. Rabinowitz J, Levine SZ, Brill N, Bromet EJ (2007) The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res 90:255-257
42. Rajkumar AP, Chitra C, Bhuvaneshwari S, Poonkuzhali B, Kuruvilla A, Jacob KS (2012) Clinical predictors of response to clozapine in patients with Treatment Resistant Schizophrenia. Psychopharmacol Bull 44 (in press)
43. Rammes G, Hosp C, Eisensamer B, Tanasic S, Nothdurfter C, Zieglgansberger W, Rupprecht R (2009) Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors. PLoS One 4:e6715
44. Remington G, Saha A, Chong SA, Shammi C (2005) Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19:843-872
45. Schuhmacher A, Mossner R, Quednow BB, Kuhn KU, Wagner M, Cvetanovska G, Rujescu D, Zill P, Moller HJ, Rietschel M, Franke P, Wolwer W, Gaebel W, Maier W (2009) Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenet Genomics 19:843-851
46. Schulte PF (2006) Risk of clozapine-associated agranulocytosis andmandatory white blood cellmonitoring. Ann Pharmacother 40:683-688
47. Solanki RK, Singh P, Munshi D (2009) Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry 51:254-260
48. Souza RP, de Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2010) Influence of serotonin 3Aand 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 20:274-276
49. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Borglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Bottcher Y, Olesen J, Breuer R, Moller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Rethelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA (2009) Common variants conferring risk of schizophrenia. Nature 460:744-747
50. Tandon R, Fleischhacker WW (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145-155
51. WHO (2001) WHODAS II Disability Assessment Schedule: 12-item interviewer administered version. World Health Organization, Geneva
52. Wongsinsup C, Taesotikul W, Kaewvichit S, Sangsrijan S, Sangsrija S (2010) Determination of clozapine in human plasma by highperformance liquid chromatography with UV-Vis detector. CMU J Nat Sci 9:29-37
53. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG (2005) Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 115:1539-1547